PMID- 34888223
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20211211
IS  - 2228-5881 (Print)
IS  - 2251-7308 (Electronic)
IS  - 2228-5881 (Linking)
VI  - 11
IP  - 4
DP  - 2021 Sep
TI  - miR-146a-5p and miR-193a-5p Synergistically Inhibited the Proliferation of Human 
      Colorectal Cancer Cells (HT-29 cell line) through ERK Signaling Pathway.
PG  - 755-764
LID - 10.34172/apb.2021.085 [doi]
AB  - Purpose: The expression of miR-146a-5p and miR-193a-5p in colorectal cancer (CRC) 
      is associated with cancer development, metastasis, and reduced survival rate of 
      the tumor-suffered subjects. This examination aimed to assess the impact of these 
      microRNAs (miRNAs) in CRC and their mechanisms in the proliferation and migration 
      of cancer cells. Methods: miR-146a-5p and -193a-5p were transfected into the 
      HT-29 cell line and assessed their impact on metastasis-related genes. The 
      synergistic effects of these miRNAs on migration were evaluated by wound healing 
      approach. To assess the influence of these miRNAs on the proliferation of and 
      apoptosis of cells, the MTT test, annexin V staining test, and DAPI staining test 
      were done. Then, the protein expression of extracellular-signal-regulated kinase 
      (ERK) and phosphorylated ERK (p-ERK) were investigated. Results: miR-146a-5p 
      and-193a-5p could inhibit the CRC cells proliferation, and could synergistically 
      induce apoptosis in CRC cells, and also repressed cell migration, and could 
      reduce p-ERK expression. Conclusion: miR-146a-5p and-193a-5p have an important 
      role in cell viability and proliferation via ERK signaling pathway. Thus, the 
      simultaneous use of these miRNAs may be suggested as a probable therapeutic 
      strategy in this cancer therapy.
CI  - (c) 2021 The Authors.
FAU - Noorolyai, Saeed
AU  - Noorolyai S
AUID- ORCID: 0000-0001-9686-0854
AD  - Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
FAU - Baghbani, Elham
AU  - Baghbani E
AD  - Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
AD  - Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran.
FAU - Shanehbandi, Dariush
AU  - Shanehbandi D
AD  - Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
FAU - Khaze Shahgoli, Vahid
AU  - Khaze Shahgoli V
AD  - Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
FAU - Baghbanzadeh Kojabad, Amir
AU  - Baghbanzadeh Kojabad A
AD  - Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
FAU - Mansoori, Behzad
AU  - Mansoori B
AD  - Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
FAU - Hajiasgharzadeh, Khalil
AU  - Hajiasgharzadeh K
AD  - Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
AD  - Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran.
FAU - Mokhtarzadeh, Ahad
AU  - Mokhtarzadeh A
AUID- ORCID: 0000-0002-4515-8675
AD  - Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
FAU - Baradaran, Behzad
AU  - Baradaran B
AUID- ORCID: 0000-0002-8642-6795
AD  - Pharmaceutical Analysis Research Center,Tabriz University of Medical Sciences, 
      Tabriz, Iran.
LA  - eng
PT  - Journal Article
DEP - 20200908
PL  - Iran
TA  - Adv Pharm Bull
JT  - Advanced pharmaceutical bulletin
JID - 101578021
PMC - PMC8642791
OTO - NOTNLM
OT  - Cell growth
OT  - Colorectal cancer
OT  - ERK pathway
OT  - miRNA-146a-5p
OT  - miRNA-193a-5p
EDAT- 2021/12/11 06:00
MHDA- 2021/12/11 06:01
PMCR- 2020/09/08
CRDT- 2021/12/10 06:45
PHST- 2020/05/27 00:00 [received]
PHST- 2020/08/13 00:00 [revised]
PHST- 2020/09/07 00:00 [accepted]
PHST- 2021/12/10 06:45 [entrez]
PHST- 2021/12/11 06:00 [pubmed]
PHST- 2021/12/11 06:01 [medline]
PHST- 2020/09/08 00:00 [pmc-release]
AID - 10.34172/apb.2021.085 [doi]
PST - ppublish
SO  - Adv Pharm Bull. 2021 Sep;11(4):755-764. doi: 10.34172/apb.2021.085. Epub 2020 Sep 
      8.